Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vitae Pharmaceuticals, Inc (VTAE)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-16 | Mar-31-16 | Dec-31-15 | Sep-30-15 | Jun-30-15 | Mar-31-15 | Dec-31-14 | Sep-30-14 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 6.2 |
| Revenue growth | -98.0% | -65.8% | -43.0% | -97.2% | -86.0% | -87.2% | -100.0% | 15.4% |
| Cost of goods sold | 0.0 | 0.0 | 33.4 | 0.0 | 0.0 | 0.0 | 21.1 | 0.0 |
| Gross profit | 0.0 | 0.1 | -33.3 | 0.2 | 0.2 | 0.2 | -20.9 | 6.2 |
| Gross margin | 100.0% | 100.0% | -36118.9% | 100.0% | 100.0% | 100.0% | -12943.7% | 100.0% |
| Selling, general and administrative [+] | 2.7 | 2.5 | 2.3 | 2.7 | 2.3 | 2.1 | 2.2 | 3.1 |
| General and administrative | 2.7 | 2.5 | 2.3 | 2.7 | 2.3 | 2.1 | 2.2 | 3.1 |
| Research and development | 7.9 | 7.6 | 9.6 | 10.7 | 7.8 | 7.5 | 5.1 | 4.8 |
| Other operating expenses | | | -33.4 | | | | -21.1 | |
| EBITDA [+] | -10.5 | -10.0 | -11.7 | -13.1 | -9.8 | -9.4 | -7.1 | -1.7 |
| EBITDA growth | 6.8% | 6.5% | 66.4% | 687.4% | 94.8% | 105.4% | -100.1% | -427.7% |
| EBITDA margin | -320129.7% | -19522.9% | -12739.6% | -7456.7% | -6074.3% | -6268.2% | -4360.8% | -26.9% |
| Depreciation and amortization | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 |
| EBIT [+] | -10.5 | -10.1 | -11.8 | -13.2 | -9.9 | -9.5 | -7.1 | -1.7 |
| EBIT growth | 6.7% | 6.5% | 65.9% | 666.3% | 93.9% | 104.3% | -100.1% | -438.1% |
| EBIT margin | -321794.0% | -19633.3% | -12803.9% | -7488.5% | -6108.5% | -6301.1% | -4396.4% | -27.8% |
| Interest income, net [+] | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | -0.2 | -0.2 |
| Interest expense | | | | 0.0 | | 0.1 | 0.2 | 0.2 |
| Interest income | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Other income (expense), net [+] | | | 0.3 | | 0.0 | -0.2 | | 0.1 |
| Gain (loss) on debt retirement | | | | | | -0.2 | | |
| Other non-operating income | | | | | 0.0 | | | 0.1 |
| Other | 0.1 | 0.1 | 0.3 | 0.1 | 0.0 | -0.2 | 0.7 | 0.1 |
| Pre-tax income | -10.4 | -10.0 | -11.4 | -13.1 | -9.8 | -9.7 | -7.3 | -1.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -10.4 | -10.0 | -11.4 | -13.1 | -9.8 | -9.7 | -7.3 | -1.8 |
| Net margin | -317961.1% | -19488.1% | -12431.9% | -7433.9% | -6040.9% | -6461.1% | -4499.8% | -29.3% |
| |
| Basic EPS [+] | ($0.36) | ($0.44) | ($0.52) | ($0.60) | ($0.45) | ($0.47) | ($0.40) | ($1.06) |
| Growth | -19.2% | -4.8% | 29.9% | -43.4% | -94.7% | -94.3% | -102.6% | -432.5% |
| Diluted EPS [+] | ($0.36) | ($0.44) | ($0.53) | ($0.60) | ($0.45) | ($0.47) | ($1.38) | ($1.06) |
| Growth | -19.2% | -4.8% | -61.5% | -43.4% | -94.7% | -94.3% | -109.1% | -432.5% |
| |
| Shares outstanding (basic) [+] | 28.8 | 22.5 | 21.9 | 21.9 | 21.8 | 20.8 | 18.1 | 1.7 |
| Growth | 32.0% | 8.2% | 21.1% | 1176.5% | 3516.3% | 3410.9% | -96.8% | 203.2% |
| Shares outstanding (diluted) [+] | 28.8 | 22.5 | 21.6 | 21.9 | 21.8 | 20.8 | 5.3 | 1.7 |
| Growth | 32.0% | 8.2% | 308.8% | 1176.5% | 3516.3% | 3410.9% | -99.1% | 203.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|